{"id":"NCT01767155","sponsor":"AEterna Zentaris","briefTitle":"Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer","officialTitle":"Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-04","primaryCompletion":"2017-01-30","completion":"2017-01-30","firstPosted":"2013-01-14","resultsPosted":"2018-07-31","lastUpdate":"2018-07-31"},"enrollment":511,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Endometrial Cancer"],"interventions":[{"type":"DRUG","name":"AEZS-108 / zoptarelin doxorubicin","otherNames":["AEZS-108"]},{"type":"DRUG","name":"doxorubicin","otherNames":[]}],"arms":[{"label":"AEZS-108 / zoptarelin doxorubicin","type":"EXPERIMENTAL"},{"label":"doxorubicin/ standard chemotherapy","type":"ACTIVE_COMPARATOR"}],"summary":"Open-label, randomized, active-controlled, two-arm Phase III study to compare the efficacy and safety of AEZS-108 and doxorubicin.","primaryOutcome":{"measure":"Compare the Overall Survival (OS) of Patients Treated With AEZS-108 to the OS of Patients Treated With Doxorubicin.","timeFrame":"From randomization to death from any cause. During ongoing treatment: response evaluation every 3 cycles. For patients gone of treatment: re-assessment every 12 weeks.","effectByArm":[{"arm":"AEZS-108 / Zoptarelin Doxorubicin","deltaMin":196,"sd":null},{"arm":"Doxorubicin/ Standard Chemotherapy","deltaMin":188,"sd":null}],"pValues":[{"comp":"OG000","p":null},{"comp":"OG000","p":null},{"comp":"OG001","p":null},{"comp":"OG001","p":null},{"comp":"OG000 vs OG001","p":"0.5441"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":123,"countries":["United States","Austria","Belarus","Belgium","Bosnia and Herzegovina","Bulgaria","Canada","Czechia","Denmark","Finland","Germany","Ireland","Israel","Italy","Netherlands","Norway","Poland","Romania","Russia","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":["36124638"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":92,"n":252},"commonTop":["Neutropenia","Nausea","Aneamia"]}}